Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in metastatic CNS cancers Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in metastatic CNS cancers